ReviewMolecular biology reports2026
The role of MicroRNAs in Alzheimer's disease: from pathogenesis to therapeutic potential.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a major neurodegenerative disorder that severely impacts the global elderly population. It is characterized by progressive memory loss, cognitive impairment, and neuropsychiatric disturbances. To date, AD lacks definitive curative treatments, making it a persistent clinical challenge. Consequently, there is an urgent need to develop cost-effective and highly specific biomarkers for the early detection of AD. MicroRNAs (miRNAs) are evolutionarily conserved, small non-coding RNAs. They are highly enriched in the central nervous system (CNS), where they orchestrate essential processes like axonal outgrowth, dendritic arborization, and synaptic plasticity. In AD patients, miRNAs actively regulate disease progression and exhibit abnormal expression profiles in peripheral blood. By modulating target genes across key pathological pathways-including β-amyloid (Aβ) aggregation, tau hyperphosphorylation, and neuroinflammation-miRNAs act as pivotal regulators of AD initiation. Therefore, systematically investigating their diagnostic and therapeutic potential could drive the development of innovative AD management strategies.
Indexed as
Identifiers
41915112What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.